Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 32.82 as of 2026-10-06T12:50:33.473Z.
Consensus retrieved: 2026-10-06T09:04:10.034Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:50:33.473Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 098b8cc383d7c70bc2f58c50adf850e5cd93194028a42938ba247026a8eec5c0
Forward PE Ratio (32.82) = Dated Quote Price ($10.72) / Consensus Forward EPS ($0.33)
FORWARD PE RATIO
32.82
SECTOR MEDIAN · HEALTHCARE
19.20
median of 132 covered companies
CURRENT VS SECTOR MEDIAN
+70.89%
vs the sector median at left
Alphatec Holdings, Inc.
Market Cap
$1.65B
Forward PE Ratio
32.82
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | $1.65B | 32.82 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 7.83 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 5.61 |
| Certara, Inc. (CERT)vs › | $1.57B | 29.56 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 46.82 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 51.14 |
| Innoviva, Inc. (INVA)vs › | $1.52B | 8.53 |
| GH Research PLC (GHRS)vs › | $1.52B | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | N/A |
| Generate Biomedicines, Inc. (GENB)vs › | $1.78B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
32.8
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $10.72, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.33 | $0.32 – $0.33 | 6 | 32.8x |
| 2027-12-31 | $0.61 | $0.58 – $0.63 | 7 | 17.6x |
| 2028-12-31 | $0.88 | $0.87 – $0.90 | 6 | 12.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
